Ocular immunology and inflammation · 2016
Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chaput Florence, Amer Radgonde, Baglivo Edoardo, Touitou Valerie, Kozyreff Alexandra, Bron Dominique, Bodaghi Bahram, LeHoang Phuc, Bergstrom Chris, Grossniklaus Hans E, Chan Chi-Chao, Pe'er Jacob, Caspers Laure E
Аннотация
PURPOSE: To report on the clinical data of seven patients with T-cell intraocular lymphoma (IOL).
METHODS: Retrospective case series.
RESULTS: Seven immunocompetent patients, 12 eyes, 6 women, with T-cell-IOL were included from five countries. Mean age was 53.5 years (range: 25-82). Four patients had systemic-ocular lymphoma, two had CNS-ocular lymphoma, and one had systemic-CNS- ocular lymphoma. Vitritis was the most frequent clinical sign, followed by anterior uveitis and serous retinal detachment. Cytopathologic examination was performed on all ocular specimens (vitreous in six and iris mass biopsy in one patient). Adjunctive diagnostic procedures included immunohistochemistry, molecular tests, and cytokine profiling of vitreous samples. Treatment modalities included systemic chemotherapy (five patients), intravitreal methotrexate (three patients), globe radiotherapy, and intrathecal chemotherapy. Mean survival from diagnosis was 21.7 months (range: 2-69). Two patients are still alive.
CONCLUSIONS: T-cell IOL has variable clinical manifestations and prognosis. Systemic involvement, SRD, and vitreoretinal involvement were frequently observed.
METHODS: Retrospective case series.
RESULTS: Seven immunocompetent patients, 12 eyes, 6 women, with T-cell-IOL were included from five countries. Mean age was 53.5 years (range: 25-82). Four patients had systemic-ocular lymphoma, two had CNS-ocular lymphoma, and one had systemic-CNS- ocular lymphoma. Vitritis was the most frequent clinical sign, followed by anterior uveitis and serous retinal detachment. Cytopathologic examination was performed on all ocular specimens (vitreous in six and iris mass biopsy in one patient). Adjunctive diagnostic procedures included immunohistochemistry, molecular tests, and cytokine profiling of vitreous samples. Treatment modalities included systemic chemotherapy (five patients), intravitreal methotrexate (three patients), globe radiotherapy, and intrathecal chemotherapy. Mean survival from diagnosis was 21.7 months (range: 2-69). Two patients are still alive.
CONCLUSIONS: T-cell IOL has variable clinical manifestations and prognosis. Systemic involvement, SRD, and vitreoretinal involvement were frequently observed.
Предметные рубрики MeSH
AdultAgedAged, 80 and overCentral Nervous System NeoplasmsEye NeoplasmsFemaleHumansImmunosuppressive AgentsInjections, SpinalIntraocular LymphomaIntravitreal InjectionsLymphoma, T-CellMaleMethotrexateMiddle AgedRadiotherapyRetrospective StudiesTertiary Care CentersTreatment OutcomeVisual AcuityVitrectomy